These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21880260)

  • 1. [Histone methyltransferases: a new class of therapeutic targets in cancer treatment?].
    Chaib H; Prébet T; Vey N; Collette Y
    Med Sci (Paris); 2011; 27(8-9):725-32. PubMed ID: 21880260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Histone Methylation in Cancer.
    McCabe MT; Mohammad HP; Barbash O; Kruger RG
    Cancer J; 2017; 23(5):292-301. PubMed ID: 28926430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone modification enzymes: novel targets for cancer drugs.
    Kristeleit R; Stimson L; Workman P; Aherne W
    Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Targeted epigenetic therapy of cancer. Achievements and perspectives].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Cir Cir; 2012; 80(5):470-80. PubMed ID: 23351455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
    Morera L; Lübbert M; Jung M
    Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic cancer therapy: Proof of concept and remaining challenges.
    Mund C; Lyko F
    Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies?
    Michalak EM; Visvader JE
    Mol Oncol; 2016 Dec; 10(10):1497-1515. PubMed ID: 27717710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors.
    Marks PA; Richon VM; Miller T; Kelly WK
    Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer treatment of the future: inhibitors of histone methyltransferases.
    Spannhoff A; Sippl W; Jung M
    Int J Biochem Cell Biol; 2009 Jan; 41(1):4-11. PubMed ID: 18773966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
    Zagni C; Chiacchio U; Rescifina A
    Curr Med Chem; 2013; 20(2):167-85. PubMed ID: 23210854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.
    Mohammad HP; Barbash O; Creasy CL
    Nat Med; 2019 Mar; 25(3):403-418. PubMed ID: 30842676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting histone lysine methylation in cancer.
    McGrath J; Trojer P
    Pharmacol Ther; 2015 Jun; 150():1-22. PubMed ID: 25578037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
    Lee SH; Kim J; Kim WH; Lee YM
    Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylases and cancer: causes and therapies.
    Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
    Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic modulators as therapeutic targets in prostate cancer.
    Graça I; Pereira-Silva E; Henrique R; Packham G; Crabb SJ; Jerónimo C
    Clin Epigenetics; 2016; 8():98. PubMed ID: 27651838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NF-κB: Regulation by Methylation.
    Lu T; Stark GR
    Cancer Res; 2015 Sep; 75(18):3692-5. PubMed ID: 26337909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
    Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
    Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.